Targeting FGF19/FGFR4 Pathway: A Novel Therapeutic Strategy for Hepatocellular Carcinoma.
Targeting FGF19/FGFR4 Pathway: A Novel Therapeutic Strategy for Hepatocellular Carcinoma.
复制标题
DOI：
10.3390/diseases3040294
复制
发表时间：
2015-10-28
期刊：
影响因子：
--
通讯作者：
Ross P
中科院分区：
文献类型：
--
作者：
Repana D;Ross P
肝细胞癌（HCC）是一种致命的癌症，全身治疗选择有限。肝癌的发生是一个复杂的过程，多种通路被发现是新的治疗方法的潜在靶点。通过FGF19及其受体FGFR4的异常信号传导似乎是hcc亚群的致癌驱动因素，并与不良预后相关。在临床前模型中抑制该通路显示出抗肿瘤活性，并引发了对体内模型的进一步评估。本综述旨在描述FGF19/FGFR4通路在肝细胞癌中的作用，以及它作为针对FGF19/FGFR4信号传导的新型靶向药物的潜在预测性生物标志物的作用。
Hepatocellular carcinoma (HCC) is a lethal cancer with limited systemic therapeutic options. Liver carcinogenesis is a complex procedure and various pathways have been found to be deregulated which are potential targets for novel treatments. Aberrant signalling through FGF19 and its receptor FGFR4 seems to be the oncogenic driver for a subset of HCCs and is associated with poor prognosis. Inhibition of the pathway in preclinical models has shown antitumour activity and has triggered further evaluation of this strategy to in vivo models. This review aims to describe the role of the FGF19/FGFR4 pathway in hepatocellular carcinoma and its role as a potential predictive biomarker for novel targeted agents against FGF19/FGFR4 signalling.